<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TREPROSTINIL SODIUM</span><br/>(tre-pros'tin-il)<br/><span class="topboxtradename">Remodulin<br/></span><b>Classifications:</b> <span class="classification">prostaglandin</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Epoprostenol<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 mg/mL, 2.5 mg/mL, 5 mg/mL, 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Causes direct vasodilation of the pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation. The
         vasodilatory effects reduce right and left ventricular afterload, and increase cardiac output and stroke volume. Also improves
         dyspnea, fatigue, and signs and symptoms of pulmonary arterial hypertension (PAH).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Vasodilation of the arteries in the pulmonary system results in lowering of pulmonary arterial hypertension (PAH).</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of pulmonary arterial hypertension (PAH) in patients with severe heart failure.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Severe intermittent claudication</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe hepatic insufficiency; hypersensitivity to treprostinil.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Mild or moderate hepatic insufficiency; bleeding disorders; concurrent use of anticoagulants, <small>NSAID</small>s, hypotensive drugs (e.g., diuretics, antihypertensive agents, etc.); lactation, pregnancy (category B); elderly. Safety
         and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pulmonary Arterial Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span>
<i>&gt;16 y,</i> 1.25 ng/kg/min. If dose is not tolerated, reduce to 0.625 ng/kg/min. Then increase rate by no more than 1.25 ng/kg/min/wk
               for first 4 wk, then by 2.5 ng/kg/min/wk until achieve desired response. There is little experience with doses &gt;40 ng/kg/min<br/><br/><span class="indicationtitle">Transition from Epoprostenol to Treprostinil</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span>
<i>&gt;16 y,</i> While still receiving IV epoprostenol, initiate a dose of SC treprostinil no greater than one-half of the current epoprostenol
               dose (generally <img src="../images/special/lesserorequal.gif"/>5 ng/kg/min). Maintain treprostinil at this dose for at least
               6 h. During this time, reduce the epoprostenol dose in no greater than 2 ng/kg/min decrements, based on appearance of prostacyclin-related
               signs and symptoms. Continue to increase treprostinil dose by no more than one-half of the current dose and maintain for 6
               h while reducing epoprostenol dose by no greater than 2 ng/kg/min decrements until epoprostenol is discontinued.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Initiate therapy only in a setting with adequate personnel and equipment for physiological monitoring and emergency.</li>
<li>Administer Remodulin undiluted.</li>
<li>Avoid abrupt withdrawal or sudden large reductions in dosage as these may lead to worsening of PAH symptom.</li>
<li>Note that in patients with mild-to-moderate hepatic insufficiency, the initial dose of should be 0.625 ng/kg/min ideal body
            weight and should be increased cautiously.
         </li>
<li>Store at 15°25° C (59°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Jaw pain,</span> flushing, syncope. <span class="typehead">CNS:</span>
<span class="speceff-common">Headache,</span> dizziness. <span class="typehead">CV:</span>
<span class="speceff-common">Vasodilation,</span> edema, hypotension. <span class="typehead">GI:</span>
<span class="speceff-common">Diarrhea, nausea, vomiting.</span>
<span class="typehead">Skin:</span>
<span class="speceff-common">Rash,</span> pruritus. <span class="typehead">Other:</span>
<span class="speceff-common">Infusion site reactions (erythema, hematoma, induration, pruritus, rash, injection site pain).</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">nsaids</span>, <span class="classification">anticoagulants</span> may increase risk of bleeding; <span class="classification">antihypertensive agents</span>, <span class="classification">diuretics</span>, <span class="classification">vasodilators</span> may exacerbate hypotension; <b>ephedrine,</b>
<b>pseudoephedrine</b> may antagonize antihypertensive effects. <span class="typehead">Herbal:</span>
<b>Ephedra,</b>
<b>ma huang</b> may antagonize antihypertensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed from SC site. <span class="typehead">Onset:</span> Steady state reached in 10 h. <span class="typehead">Metabolism:</span> Extensively metabolized in liver by unknown enzyme system. <span class="typehead">Elimination:</span> 79% excreted in urine, 13% excreted in feces. <span class="typehead">Half-Life:</span> 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness indicated by less dyspnea and fatigue, increased activity tolerance, and improved hemodynamic
            parameters.
         </li>
<li>Monitor for and report symptoms of excessive response to the drug including: headache, nausea, emesis, restlessness, anxiety
            and infusion site pain or reaction (e.g., erythema, induration or rash). If these occur, the rate of SC infusion should be
            slowed.
         </li>
<li>Monitor BP closely, especially if taking concurrent antihypertensive drugs (e.g., diuretics, vasodilators).</li>
<li>Lab tests: Baseline and periodic LFTs and renal function tests. Monitor periodically coagulation parameters (more often if
            on concurrent anticoagulation therapy).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Therapy with this drug may be needed for prolonged periods, possibly years.
            						
         </li>
<li>Report any of the following: headache, nausea, vomiting, restlessness, anxiety and infusion site pain.</li>
<li>Do not breast feed while taking this drug without consulting the physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>